FDA Confirms Registrational Pathway for Alterity’s ATH434 in MSA — ALTERITY THERAPEUTICS LIMITED

Event summary

FDA meeting minutes confirm a single pivotal Phase 3 trial plus confirmatory evidence could support ATH434 approval for MSA.
Phase 3 trial design agreed upon, including primary endpoint (11-item UMSARS Part I) and key secondary endpoints.
Trial expected to enroll ~200 patients, with initiation on track by year-end 2026.

The big picture

Alterity’s FDA alignment on the Phase 3 trial design for ATH434 marks a critical step in addressing Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. The FDA’s willingness to accept a single pivotal trial reflects both the unmet medical need and the robustness of Alterity’s Phase 2 data. Success here could position ATH434 as a first-in-class therapy, potentially transforming the MSA treatment landscape.

What we're watching

Clinical Execution: Whether Alterity can initiate and complete the Phase 3 trial as planned by year-end 2026.
Regulatory Efficiency: The pace at which FDA review progresses post-trial completion, given the single pivotal trial pathway.
Market Opportunity: How ATH434’s potential approval could reshape treatment options for MSA, a disease with no current disease-modifying therapies.